Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators

References

• Morrow TH, Felcone LH. Defining the difference: what makes biologics unique. Biotechnol Healthc. 2004;1(4):24–29.
   PubMedGoogle Scholar
• Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018;17(5):353–377. doi:10.1038/nrd.2018.2129545548
   PubMed Web of Science ®Google Scholar
• Bresnihan B, Cunnane G. Infection complications associated with the use of biologic immunomodulators. Rheum Dis Clin North Am. 2003;29(1):185–202. doi:10.1016/S0889-857X(02)00101-112635507
   PubMed Web of Science ®Google Scholar
• Meroni PL, Zavaglia D, Girmenia C. Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs. Clin Exp Rheumatol. 2018;36(2):317–328.29303710
   PubMed Web of Science ®Google Scholar
• Henrickson SE, Ruffner MA, Kwan M. Unintended immunological consequences of biologic therapy. Curr Allergy Asthma Rep. 2016;16(6):46. doi:10.1007/s11882-016-0624-727324478
   PubMed Web of Science ®Google Scholar
• Kaplan B, Bonagura VR. Secondary hypogammaglobulinemia: an increasingly recognized complication of treatment with immunomodulators and after solid organ transplantation. Immunol Allergy Clin North Am. 2019;39(1):31–47. doi:10.1016/j.iac.2018.08.00530466771
   PubMed Web of Science ®Google Scholar
• Eisenberg R. Immune Compromise Associated with Biologics. Stiehm’s Immune Deficiencies Academic Press; 2014:889–906.
   Google Scholar
• Winthrop KL, Mariette X, Silva JT, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infection diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect. 2018;24:S21–S40. doi:10.1016/j.cmi.2018.02.00229447987
   PubMed Web of Science ®Google Scholar
• Reinwald M, Silva JT, Mueller NJ, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infection diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect. 2018;24:S53–70. doi:10.1016/j.cmi.2018.02.00929454849
   PubMed Web of Science ®Google Scholar
• Mikulska M, Lanini S, Gudiol C, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infection diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect. 2018;24:S71–S82.29447988
   PubMed Web of Science ®Google Scholar
• Redelman-Sidi G, Michielin O, Cervera C, et al. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infection diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). Clin Microbiol Infect. 2018;24:S95–S107. doi:10.1016/j.cmi.2018.01.03029427804
   PubMed Web of Science ®Google Scholar
• Drgona L, Gudiol C, Lanini S, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infection diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect. 2018;24:S83–S94. doi:10.1016/j.cmi.2018.03.02229572070
   PubMed Web of Science ®Google Scholar
• Baddley JW, Cantini F, Goletti D, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents). Clin Microbiol Infect. 2018;24:S10–S20. doi:10.1016/j.cmi.2017.12.02529459143
   PubMed Web of Science ®Google Scholar
• Baden LR, Swaminathan S, Angarone M, et al. Prevention and treatment of cancer-related infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14(7):882–913. doi:10.6004/jnccn.2016.009327407129
   PubMed Web of Science ®Google Scholar
• Kotton CN, Kumar D, Caliendo AM, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102(6):900–931. doi:10.1097/TP.000000000000219129596116
   PubMed Web of Science ®Google Scholar
• Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2013;58(3):e44–e100.24311479
   PubMed Web of Science ®Google Scholar
• Martin SI, Fishman JA, AST Infection Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplantation. Am J Transplant. 2013;13(s4):272–279. doi:10.1111/ajt.2013.13.issue-s423465020
   PubMed Web of Science ®Google Scholar
• Van Assen S, Elkayam O, Agmon-Levin N, et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev. 2011;10(6):341–352. doi:10.1016/j.autrev.2010.12.00321182987
   PubMed Web of Science ®Google Scholar
• Salinas GF, De Rycke L, Barendregt B, et al. Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis. 2013;72(6):1037–1043. doi:10.1136/annrheumdis-2011-20127022968102
   PubMed Web of Science ®Google Scholar
• Farraye FA, Melmed GY, Lichtenstein GR, et al. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112(2):241. doi:10.1038/ajg.2016.53728071656
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26. doi:10.1002/art.39480
   PubMed Web of Science ®Google Scholar
• Wijetilleka S, Jayne DR, Mukhtyar C, et al. Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted immunomodulators in autoimmune rheumatic diseases. Rheumatology. 2018;58(5):889–896. doi:10.1093/rheumatology/key394
   Web of Science ®Google Scholar
• Mikulska M, Cesaro S, de Lavallade H, et al. Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(6). doi:10.1016/S1473-3099(18)30601-7
   Web of Science ®Google Scholar
• Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(5):1–30.
   PubMedGoogle Scholar
• Kroger AT, Duchin J, Vázquez M. General best practice guidelines for immunization. best practices guidance of the advisory committee on immunization practices (ACIP). Available from: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html. Accessed 129, 2020.
   Google Scholar
• Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71(9):2397–2404. doi:10.1093/jac/dkw15727550992
   PubMed Web of Science ®Google Scholar
• Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):215–219. doi:10.1053/j.gastro.2014.10.03925447850
   PubMed Web of Science ®Google Scholar
• Rieger CT, Liss B, Mellinghoff S, et al. Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors. Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Oncol. 2018;29(6):1354–1365. doi:10.1093/annonc/mdy11729688266
   PubMed Web of Science ®Google Scholar
• Subramanian AK, Theodoropoulos NM. Mycobacterium tuberculosis infections in solid organ transplantation: Guidelines from the infectious diseases community of practice of the American Society of Transplantation. Clin Transplant. 2019 9;33(9):e13513. doi:10.1111/ctr.1351330817030
   PubMed Web of Science ®Google Scholar
• Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152(6):1297–1309. doi:10.1053/j.gastro.2017.02.00928219691
   PubMed Web of Science ®Google Scholar
• Ciardi MR, Iannetta M, Zingaropoli MA, et al. Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis. Open Forum Infect Dis. 2018;6(1):ofy356.30697576
   PubMed Web of Science ®Google Scholar
• Li HR, Huang JJ, Guo HQ, et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat. 2011;18(12):877–883. doi:10.1111/j.1365-2893.2010.01386.x21054683
   PubMed Web of Science ®Google Scholar
• Picardi M, Della Pepa R, Giordano C, et al. Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL. Blood. 2019;133(5):498. doi:10.1182/blood-2018-10-87889230530802
   PubMed Web of Science ®Google Scholar
• Chen YM, Huang WN, Wu YD, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study. Ann Rheum Dis. 2018;77(5):780–782. doi:10.1136/annrheumdis-2017-21132228663308
   PubMed Web of Science ®Google Scholar
• Göksu SS, Bilal Ş, Coşkun HŞ. Hepatitis B reactivation related to everolimus. World J Hepatol. 2013;5(1):43. doi:10.4254/wjh.v5.i1.4323383366
   PubMedGoogle Scholar
• Mizuno S, Yamagishi Y, Ebinuma H, et al. Progressive liver failure induced by everolimus for renal cell carcinoma in a 58-year-old male hepatitis B virus carrier. Clin J Gastroenterol. 2013;6(2):188–192. doi:10.1007/s12328-013-0371-423606919
   PubMedGoogle Scholar
• Swan CD, Reid AB. Three cases of presumed pneumocystis pneumonia in patients receiving bortezomib therapy for multiple myeloma. IDCases. 2014;1(3):32–35. doi:10.1016/j.idcr.2014.04.00226955521
   PubMedGoogle Scholar
• Wondergem MJ, Grünberg K, Wittgen BP, et al. Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment. Histopathology. 2009;54(5):631–633. doi:10.1111/j.1365-2559.2009.03263.x19302537
   PubMed Web of Science ®Google Scholar
• Tabanor JA, Lakshminarayanan S. Do patients on biologic drugs for rheumatic disease need PCP prophylaxis? Cleve Clin J Med. 2019;86(7):449–453. doi:10.3949/ccjm.86a.1808431291178
   PubMed Web of Science ®Google Scholar
• Mori S, Yoshitama T, Hidaka T, et al. Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: a multicenter retrospective cohort study in Japan. PLoS One. 2017;12(6):e0179179. doi:10.1371/journal.pone.017917928594905
   PubMed Web of Science ®Google Scholar
• Lee R, Nayernama A, Jones SC, et al. Ibrutinib‐associated Pneumocystis jirovecii pneumonia. Am J Hematol. 2017;92(11):E646–E648. doi:10.1002/ajh.2489028815693
   PubMed Web of Science ®Google Scholar
• Noreña I, Fernández-Ruiz M, Aguado JM. Viral infections in the biologic therapy era. Expert. Rev Anti Infect Ther. 2018;16(10):781–791. doi:10.1080/14787210.2018.1521270
   PubMed Web of Science ®Google Scholar
• Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009;10(8):816–824. doi:10.1016/S1470-2045(09)70161-519647202
   PubMed Web of Science ®Google Scholar
• Blankenbach K, Schwab N, Hofner B, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in Germany. Neurology. 2019;92(19):e2232–e2233. doi:10.1212/WNL.000000000000745130952796
   PubMed Web of Science ®Google Scholar
• Siegler JE, Galetta S. Editors’ note: progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology. 2019;92(3):150. doi:10.1212/WNL.000000000000677230643031
   PubMed Web of Science ®Google Scholar
• Lalive PH, Roth S, Du Pasquier R. Reader response: progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology. 2019;92(3):151. doi:10.1212/WNL.0000000000006773
   Web of Science ®Google Scholar
• Bigaut K, De Seze J, Collongues N. Ocrelizumab for the treatment of multiple sclerosis. Expert Rev Neurother. 2019;19(2):97–108. doi:10.1080/14737175.2019.156128430570368
   PubMed Web of Science ®Google Scholar
• Williamson EM, Berger JR. Diagnosis and treatment of progressive multifocal leukoencephalopathy associated with multiple sclerosis therapies. Neurotherapeutics. 2017;14(4):961–973. doi:10.1007/s13311-017-0570-728913726
   PubMed Web of Science ®Google Scholar
• Ai JW, Zhang S, Ruan QL, et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-α antagonist: a meta analysis of both randomized controlled trials and registry/cohort studies. J Rheumatol. 2015;42(12):2229–2237. doi:10.3899/jrheum.15005726472414
   PubMed Web of Science ®Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275–2285. doi:10.1001/jama.295.19.227516705109
   PubMed Web of Science ®Google Scholar
• Souto A, Maneiro JR, Salgado E, et al. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology. 2014;53(10):1872–1885. doi:10.1093/rheumatology/keu17224821849
   PubMed Web of Science ®Google Scholar
• Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis. 2006;43(6):717–722.16912945
   PubMed Web of Science ®Google Scholar
• Lussana F, Cattaneo M, Rambaldi A, et al. Ruxolitinib‐associated infections: a systematic review and meta‐analysis. Am J Hematol. 2018;93(3):339–347. doi:10.1002/ajh.2497629150886
   PubMed Web of Science ®Google Scholar
• Cantini F, Nannini C, Niccoli L, et al. Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics. Mediators Inflamm. 2017;2017:8909834. doi:10.1155/2017/890983428659665
   PubMed Web of Science ®Google Scholar
• Helfrich M, Ison MG. Opportunistic infections complicating solid organ transplantation with alemtuzumab induction. Transpl Infect Dis. 2015;17(5):627–636. doi:10.1111/tid.2015.17.issue-526228653
   PubMed Web of Science ®Google Scholar
• Au WY, Leung AY, Eric WC, et al. High incidence of tuberculosis after alemtuzumab treatment in Hong Kong Chinese patients. Leuk Res. 2008;32(4):547–551. doi:10.1016/j.leukres.2007.06.01017714782
   PubMed Web of Science ®Google Scholar
• Jeon SY, Yhim HY, Lee NR, et al. Everolimus-induced activation of latent Mycobacterium tuberculosis infection in a patient with metastatic renal cell carcinoma. Korean J Intern Med. 2017;32(2):365–368. doi:10.3904/kjim.2015.12126837008
   PubMed Web of Science ®Google Scholar
• Coriat R, Mir O, Ropert S, et al. Reactivation of tuberculosis during temsirolimus therapy. Invest New Drugs. 2011;29(6):1494–1496. doi:10.1007/s10637-010-9487-220623161
   PubMed Web of Science ®Google Scholar
• Guirao-Arrabal E, Santos F, Redel‐Montero J, et al. Risk of tuberculosis after lung transplantation: the value of pretransplant chest computed tomography and the impact of m TOR inhibitors and azathioprine use. Transpl Infect Dis. 2016;18(4):512–519. doi:10.1111/tid.1255527224905
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009;49(8):1211–1225. doi:10.1086/59919119769539
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(10):2675–2684. doi:10.1002/art.v66.1024943354
   PubMed Web of Science ®Google Scholar
• Yun H, Xie F, Delzell E, et al. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken). 2015;67(5):731–736. doi:10.1002/acr.2247025201241
   PubMed Web of Science ®Google Scholar
• Arvin AM, Wolinsky JS, Kappos L, et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015;72(1):31–39. doi:10.1001/jamaneurol.2014.306525419615
   PubMed Web of Science ®Google Scholar
• Buonomo AR, Zappulo E, Viceconte G, et al. Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. Expert Opin Drug Saf. 2018;17(7):709–717. doi:10.1080/14740338.2018.148333029848085
   PubMed Web of Science ®Google Scholar
• Prestes DP, Arbona E, Nevett-Fernandez A, et al. Dasatinib use and risk of cytomegalovirus reactivation after allogeneic hematopoietic-cell transplantation. Clin Infect Dis. 2017;65(3):510–513. doi:10.1093/cid/cix32528419210
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). International non- proprietary name: remicade. European Medicines Agency EMA/CHMP/47828/2019. Available from: https://www.ema.europa.eu/en/documents/product-information/remicade-epar-product-information_en.pdf. Accessed 129, 2020.
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). International non- proprietary name: kineret. Available from: https://www.ema.europa.eu/en/documents/product-information/kineret-epar-product-information_en.pdf. Accessed 129, 2020.
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). International non- proprietary name: ilaris ‎EMEA/H/C/001109. Available from: https://www.ema.europa.eu/en/documents/product-information/ilaris-epar-product-information_en.pdf. Accessed 129, 2020.
   Google Scholar
• Alten R, Bingham CO, Cohen SB, et al. Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. BMC Musculoskelet Disord. 2016;17(1):231. doi:10.1186/s12891-016-1082-z27229685
   PubMed Web of Science ®Google Scholar
• Chatham W, Chadha A, Fettiplace J, et al. A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus. Lupus. 2017;26(14):1483–1490. doi:10.1177/096120331770349528467293
   PubMed Web of Science ®Google Scholar
• Kaufman M, Pardo G, Rossman H, Sweetser MT, Forrestal F, Duda P. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. J Neurol Sci. 2014;341(1–2):22–27. doi:10.1016/j.jns.2014.03.03524731783
   PubMed Web of Science ®Google Scholar
• Brodmerkel C, Wadman E, Langley RG, et al. Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use. J Drugs Dermatol. 2013;12(10):1122–1129.24085047
   PubMed Web of Science ®Google Scholar
• Chioato A, Noseda E, Stevens M, et al. Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study. Clin Vaccine Immunol. 2012;19(10):1597–1602. doi:10.1128/CVI.00386-1222875601
   PubMed Web of Science ®Google Scholar
• Mori S, Ueki Y, Hirakata N, et al. Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis. 2012;71(12):2006–2010. doi:10.1136/annrheumdis-2012-20195022887851
   PubMed Web of Science ®Google Scholar
• Celotto K, Nair J, Lee K. The effect of bortezomib treatment on antibody titers against common viral and vaccine antigens. Clin Lymph Myelom Leuk. 2015;15:e179. doi:10.1016/j.clml.2015.07.402
   Google Scholar
• Berger T, Elovaara I, Fredrikson S, et al. Alemtuzumab use in clinical practice: recommendations from European multiple sclerosis experts. CNS Drugs. 2017;31(1):33–50. doi:10.1007/s40263-016-0394-827882532
   PubMed Web of Science ®Google Scholar
• Issa NC, Baden LR. Current issues in vaccines for adult patients with hematologic malignancies. J Natl Compr Canc Netw. 2012;10(11):1447–1454. doi:10.6004/jnccn.2012.014723138170
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). International non- proprietary name: raptiva ‎EMEA/H/C/000542. Available from: https://www.ema.europa.eu/en/documents/product-information/raptiva-epar-product-information_en.pdf. Accessed 129, 2020.
   Google Scholar
• De Lavallade H, Khoder A, Hart M, et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood. 2013;122(2):227–238. doi:10.1182/blood-2012-11-46503923719297
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Silverfield J, Racewicz A, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis. 2016;75(4):687–695. doi:10.1136/annrheumdis-2014-20719125795907
   PubMed Web of Science ®Google Scholar
• Douglas AP, Trubiano JA, Barr I, Leung V, Slavin MA, Tam CS. Ibrutinib may impair serological responses to influenza vaccination. Haematologica. 2017;102(10):e397. doi:10.3324/haematol.2017.16428528659336
   PubMed Web of Science ®Google Scholar
• Struijk GH, Minnee RC, Koch SD, et al. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. Kidney Int. 2010;78(9):934–940. doi:10.1038/ki.2010.26920703211
   PubMed Web of Science ®Google Scholar
• Barmettler S, Ong MS, Farmer JR, et al. Association of immunoglobulin levels, infection risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open. 2018;1(7):e184169. doi:10.1001/jamanetworkopen.2018.416930646343
   PubMed Web of Science ®Google Scholar
• Danovitch GM, editor. Handbook of Kidney Transplantation. Lippincott Williams & Wilkins; 2017 6, 13.
   Google Scholar
• Terrault NA, Lok AS, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. doi:10.1002/hep.2980029405329
   PubMed Web of Science ®Google Scholar
• Winthrop KL. Tumor necrosis factor-alpha inhibitors: bacterial, viral, and fungal infections. Bow Blumberg EA, Bond Sh, editors. UpToDate Inc.2019 Available from: https://www.uptodate.com/contents/tumor-necrosis-factor-alpha-inhibitors-bacterial-viral-and-fungal-infections. Accessed 129, 2020.
   Google Scholar
• Morrison VA. Prevention of infections in patients with chronic lymphocytic leukemia. Bow E, Throner AR, editors. UpToDate Inc. 2019 Available from: https://www.uptodate.com/contents/prevention-of-infections-in-patients-with-chronic-lymphocytic-leukemia. Accessed 129, 2020.
   Google Scholar
• Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95. doi:10.1186/s40425-017-0300-z29162153
   PubMed Web of Science ®Google Scholar
• Fishman JA, Gans H; AST Infectious Diseases Community of Practice. Pneumocystis jiroveci in solid organ transplantation: guidelines from the american society of transplantation infectious diseases community of practice. Clin Transplant. 2019;33:e13587.31077616
   PubMed Web of Science ®Google Scholar
• Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymph Myelom Leuk. 2013;13(2):106–111. doi:10.1016/j.clml.2012.11.011
   PubMed Web of Science ®Google Scholar
• Yilmaz E, Mahani MG, Bilen MA, et al. Clinical characteristics of rituximab-induced late onset neutropenia. Am J Hematol. 2010;85(10):810–812. doi:10.1002/ajh.2181820730791
   PubMed Web of Science ®Google Scholar
• Salmon JH, Cacoub P, Combe B, et al. Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the autoimmunity and rituximab registry. RMD Open. 2015;1(1):e000034. doi:10.1136/rmdopen-2014-00003426509060
   PubMed Web of Science ®Google Scholar
• Cohen BA. Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis. Neurology. 2019;92(9):435–436. doi:10.1212/WNL.000000000000692430635476
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). International non- proprietary name: xeljanz EMEA/H/C/004214. Available from: https://www.ema.europa.eu/en/documents/product-information/xeljanz-epar-product-information_en.pdf. Accessed 129, 2020.
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). International non- proprietary name: Jakavi - EMEA/H/C/002464. Available from: https://www.ema.europa.eu/en/documents/product-information/jakavi-epar-product-information_en.pdf. Accessed 2 10, 2020.
   Google Scholar
• Click B, Regueiro M. Managing Risks with Biologics. Curr Gastroenterol Rep. 2019;21(1):1. doi:10.1007/s11894-019-0669-630635807
   PubMedGoogle Scholar
• Committee for Medicinal Products for Human Use (CHMP). International non- proprietary name: gilenya EMEA/H/C/002202. Available from: https://www.ema.europa.eu/en/documents/product-information/gilenya-epar-product-information_en.pdf. Accessed 129, 2020.
   Google Scholar
• Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39–52. doi:10.1136/annrheumdis-2019-21588231413005
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). International non- proprietary name: humira EMEA/H/C/000481. Available from: https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf. Accessed 129, 2020.
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). International non- proprietary name: enbrel. EMEA/H/C/000262l. Available from: https://www.ema.europa.eu/en/documents/product-information/enbrel-epar-product-information_en.pdf. Accessed 129, 2020.
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). International non- proprietary name: Simponi. European Medicines Agency. EMEA/H/C/000992. Available from: https://www.ema.europa.eu/en/documents/product-information/simponi-epar-product-information_en.pdf. Accessed 129, 2020.
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). International non- proprietary name: cimzia. EMEA/H/C/001037. Available from: https://www.ema.europa.eu/en/documents/product-information/cimzia-epar-product-information_en.pdf. Accessed 129, 2020.
   Google Scholar
• Papp KA, Haraoui B, Kumar D, et al. Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies. J Cutan Med Surg. 2019;23(1):50–74. doi:10.1177/120347541881133530463418
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). International non- proprietary name: regeneron EMEA/H/C/001047. Available from: https://www.ema.europa.eu/en/documents/product-information/rilonacept-regeneron-epar-product-information_en.pdf. Accessed 129, 2020.
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP) International non- proprietary name: blincyto EMEA/H/C/003731 https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf. Accessed 129, 2020.
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). International non- proprietary name: ocrevus EMA/790835/2017. Available from: https://www.ema.europa.eu/en/documents/product-information/ocrevus-epar-product-information_en.pdf. Accessed 129, 2020.
   Google Scholar
• Stokmaier D, Winthrop K, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis (S36. 002).
   Google Scholar
• Beaulieu DB, Ananthakrishnan AN, Martin C, et al. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin Gastroenterol Hepatol. 2018;16(1):99–105. doi:10.1016/j.cgh.2017.08.04128870657
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). International non- proprietary name: arzerra ‎EMEA/H/C/001131. Available from: https://www.ema.europa.eu/en/documents/product-information/arzerra-epar-product-information_en.pdf. Accessed 129, 2020.
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). International non- proprietary name: Gazyvaro - EMEA/H/C/002799. Available from:https://www.ema.europa.eu/en/documents/product-information/gazyvaro-epar-product-information_en.pdf. Accessed 2 5, 2020.
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). International non- proprietary name: mabcampath‎ EMEA/H/C/000353. Available from: https://www.ema.europa.eu/en/documents/product-information/mabcampath-epar-product-information_en.pdf. Accessed 129, 2020.
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). International non- proprietary name: orenica EMEA/H/C/000701. Available from: https://www.ema.europa.eu/en/documents/product-information/orencia-epar-product-information_en.pdf. Accessed 129, 2020.
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). International non- proprietary name: stelara EMEA/H/C/000958. Available from: https://www.ema.europa.eu/en/documents/product-information/stelara-epar-product-information_en.pdf. Accessed 129, 2020.
   Google Scholar
• Danziger Isakov L, Kumar D; AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant. 2019;33:e13563.31002409
   PubMed Web of Science ®Google Scholar